The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM

Opinion
Video

Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content